Efficacy of recombinant human vascular endostatin in combination with platinum-based regimen as the first-line therapy for patients with advanced non-small cell lung cancer / 肿瘤

ABSTRACT

Objective: To evaluate the short-term effect and the survival of patients with advanced non-small cell lung cancer (NSCLC) after receiving recombinant human vascular endostatin (Endostar) therapy in combination with standard platinum-based regimen. Methods: Forty eligible patients were recruited from May 2007 to April 2009, and they received Endostar (15 mg/d, d 1 to d 14, per 3 weeks a cycle) plus platinum-based regimen (per 3 weeks a cycle) for 4-6 cycles. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and the overall survival (OS) were evaluated. Subgroup analysis was based on the clinicopathological features. Results: Of 40 patients, 37 could be evaluated for short-term response. The ORR was 29.7%, and the DCR was 81.8%; the median PFS was 11.1 months, and the median OS was 23.0 months. Subgroup analysis showed that PFS was associated with histology (hazard ratio = 0.366; 95% confidence interval 0.160-0.840; P = 0.018) and the clinical stage (hazard ratio = 0.405; 95% confidence interval 0.174-0.942; P = 0.036). The gender, age, histology and the clinical stage were not associated with OS. Conclusion: Treatment of Endostar in combination with standard platinum-based regimen may prolong the PFS and OS of patients with advanced NSCLC. Copyright© 2011 by the Editorial Board of Tumor.